Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | MC5R | P33032 | 1/20 | 0.30 |
| ▸ | MC3R | P41968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4166104 | 0.87 | MC4R (0.33) | PTGDRMC4RMC5RMC3R | |
| Hydrochloric Acid SCHEMBL4166100 | 0.87 | MC4R (0.33) | PTGDRMC4RMC5RMC3R | |
| Hydrochloric Acid SCHEMBL4167766 | 0.87 | MC4R (0.33) | PTGDRMC4RMC5RMC3R | |
| SCHEMBL4166910 | 0.86 | KDM4E (0.39) | KDM4EPTGDRGAALMNATP53 | |
| SCHEMBL3253488 | 0.84 | KDM4E (0.37) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL3250390 | 0.84 | KDM4E (0.37) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL3250387 | 0.84 | KDM4E (0.37) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL4157860 | 0.82 | MAPT (0.37) | KDM4EGAALMNATP53MAPT | |
| SCHEMBL4159472 | 0.81 | HTR1D (0.37) | KDM4EPTGDRGAALMNATP53 | |
| SCHEMBL4155240 | 0.80 | KDM4E (0.35) | KDM4EPTGDRGAALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | KDM4E 1970/4885PTGDR 861/4885GAA 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.